ASAmelie Stenqvist

Amelie Stenqvist

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Amelie Stenqvist has a total of 15 co-authors. Here are the top co-authors by number of shared publications:

  • Aleksander Giwercman

    Molecular Reproductive Medicine, Department of Translational Medicine, Lund University, Malmö, Sweden; Reproductive Medicine Centre, Skåne University Hospital, Malmö, Sweden

    2 shared publications
  • Mona Bungum

    Reproductive Medicine Centre, Skåne University Hospital, Malmö, Sweden

    2 shared publications
  • Aleksander Giwercman

    Lund University

    1 shared publication
  • Anja Bisgaard Pinborg

    Fertility Clinic, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark

    1 shared publication
  • Anne Lis Englund

    Fertility Clinic, Zealand University Hospital, Koege, Denmark

    1 shared publication
  • Anne Zedeler

    Department of Obstetrics and Gynaecology, The Fertility Clinic, Copenhagen University Hospital Hvidovre, Hvidovre, Denmark

    1 shared publication

Latest Publications

  • Open Access

    Cumulative live birth rates under three consecutive IVF/ICSI treatment cycles are reduced in women with endometriosis and/or adenomyosis diagnosed by ultrasonography

    by Sara Alson, Amelie Stenqvist, Povilas Sladkevicius

    STUDY QUESTION: Does endometriosis and/or adenomyosis, diagnosed using the International Deep Endometriosis Analysis (IDEA) group and the Morphological Uterus Sonographic Assessment (MUSA) group revised definitions, impact cumulative live birth rates (CLBR) after three consecutive IVF or ICSI treatments? SUMMARY ANSWER: Women with endometriosis and/or adenomyosis, as diagnosed using transvaginal ultrasonography, had a 15% reduced chance of having a cumulative live birth after three consecutive IVF/ICSI treatments compared to women without these conditions. WHAT IS KNOWN ALREADY: Women with endometriosis or adenomyosis reportedly have lower live birth rates after their first IVF/ICSI treatment. However, most women undergo multiple cycles, and given their shared pathophysiology, the combined impact of both conditions over consecutive treatments remains unclear. STUDY DESIGN, SIZE, DURATION: This was a prospective cohort study of 1035 women undergoing up to three consecutive IVF/ICSI treatments at a university hospital between January 2019 and April 2024. Swedish regulations entitle women to up to three subsidized treatment cycles, including fresh and/or frozen embryo transfers, until the birth of a living child is achieved. PARTICIPANTS/MATERIALS, SETTING, METHODS: All 1035 included women underwent a transvaginal ultrasound examination prior to starting their first treatment. Using the IDEA and revised MUSA definitions, respectively, in total 293 (28.3%) women had endometriosis and/or direct features of adenomyosis on ultrasonography. All 1035 women underwent the first treatment cycle. In total, 818 (79.0%) women [595 (80.2%) of women without endometriosis and/or adenomyosis and 223 (76.1%) of women with either of the diseases] underwent all treatments they were eligible for. A total of 217 (21.0%) women dropped out after the first or second treatment even if they had not achieved a live birth. In total, 1725 fresh treatment cycles were initiated, leading to 1283 fresh and 622 frozen embryo transfers. Live births were recorded. The adjusted relative risk (aRR) for cumulative live birth after three consecutive IVF/ICSI treatment cycles was calculated on an intention-to-treat (ITT) as well as per-protocol (PP) basis, using a modified Poisson regression analysis, adjusting for age as a potential confounder. MAIN RESULTS AND THE ROLE OF CHANCE: The CLBR over three consecutive IVF/ICSI treatment cycles was 666/818 (81.4%) in the total cohort. In an ITT and PP analyses, respectively, women with endometriosis and/or adenomyosis had a lower CLBR of 156/293 (53.2%) or 156/223 (70.0%) compared to women without, CLBR of 510/742 (68.7%) or 510/595 (85.7%), P < 0.001. The aRR for cumulative live birth for women with endometriosis and/or adenomyosis was aRR (ITT) 0.80 (95% CI, 0.71–0.90), P < 0.001, and aRR (PP) 0.85 (95% CI, 0.77–0.93), P < 0.001 compared to women without the diseases. After stratifying the results per treatment cycle, the LBR after the first treatment for women with endometriosis and/or adenomyosis was 90/293 (30.7%), aRR 0.69 (95% CI 0.57–0.84), P < 0.001, after the second 44/154 (28.6%), aRR 0.72 (95% CI 0.54–0.96), P = 0.023, and after the third treatment 22/84 (26.2%), aRR 0.83 (95% CI 0.54–1.28), P = 0.183. For women without the diseases, the LBR was 335/742 (45.1%) in the first cycle, 132/319 (41.4%) in the second, and 43/133 (32.3%) in the third cycle. The largest differences were seen after fresh compared to frozen embryo transfers. LIMITATIONS, REASONS FOR CAUTION: The ultrasound examinations were performed at a tertiary care hospital by an examiner with expertise in endometriosis and adenomyosis. According to the revised MUSA definitions, direct features of adenomyosis are pathognomonic, whereas indirect features are only indicative of the disease. It is possible that some women with only indirect features, who were considered healthy in this study, in fact had the disease and therefore were wrongly classified. WIDER IMPLICATIONS OF THE FINDINGS: Despite a lower CLBR over three IVF/ICSI cycles, women with endometriosis and/or adenomyosis still have a reasonable chance of achieving a live birth with consecutive treatments. Negative results after the first treatment should not be an argument to withhold further attempts. Future research should explore strategies to enhance treatment success in this population, including the role of long-term suppression protocols, exogenous progesterone dosing, and personalized embryo transfer approaches. STUDY FUNDING/COMPETING INTEREST(S): This study was supported by regional research grants from Region Skåne, Sweden. TRIAL REGISTRATION NUMBER: N/A.


  • Open Access

    High sperm deoxyribonucleic acid fragmentation index is associated with an increased risk of preeclampsia following assisted reproduction treatment

    by Amelie Stenqvist, Mona Bungum, Anja Bisgaard Pinborg, Jeanette Bogstad, Anne Lis Englund, Marie Louise Grøndahl, Anne Zedeler, Stefan R. Hansson, Aleksander Giwercman


  • Open Access

    Sperm DNA fragmentation index and cumulative live birth rate in a cohort of 2,713 couples undergoing assisted reproduction treatment

    by Sladjana Malić Vončina, Amelie Stenqvist, Mona Bungum, Tommy Schyman, Aleksander Giwercman


  • Impact of antioxidant treatment on DNA fragmentation index: a double‐blind placebo‐controlled randomized trial

    by A. Stenqvist, K. Oleszczuk, I. Leijonhufvud, A. Giwercman

    Background: Previous reports on effect of antioxidants on sperm DNA integrity were equivocal, and there is a lack of randomized, placebo‐controlled studies.Objectives: To evaluate the efficacy of combined antioxidant treatment in subfertile men with normal reproductive hormone levels and high sperm DNA fragmentation index (DFI).Materials and methods: This placebo‐controlled, double‐blind, randomized study evaluated the effects of combined antioxidant treatment in 77 men from infertile couples, with normal testosterone, LH and FSH levels and DFI ≥25%. All participants were randomly assigned to receive combined antioxidant treatment (vitamins, antioxidants and oligoelements) or placebo for six months. The primary outcome measured was DFI. Secondary outcomes were standard semen parameters. DFI and other semen parameters were, at each time point (pre‐treatment, and after three and six months of treatment), compared between the treatment and the placebo group using Mann–Whitney U‐test.Results: Antioxidant group had higher sperm concentration after three months of treatment (median: 24.4 × 106/mL vs. 27.2 × 106/mL; P = 0.028) and borderline statistically significant higher concentration after six months of treatment (median: 24.4 × 106/mL vs. 33.3 × 106/mL; P = 0.053) compared to pre‐treatment values. The DFI did not change during the 6 months of antioxidant therapy. No statistically significant difference between the antioxidant and placebo group was seen for any of the semen parameters including sperm DFI at any of the three time points.Discussion: The increase in sperm concentration was more pronounced in the antioxidant treated group but not statistically significantly higher than among controls, perhaps due to insufficient statistical power. Previous studies have shown positive effect of antioxidant treatment on DFI and other semen parameters. However, our findings indicate that men with normal reproductive hormone levels may not be the primary target group for such therapy.Conclusion: Six months treatment with antioxidants had no effect on sperm DFI.